Tools & Resources / Document Resource Library / Documents / [IO Summit 2022] Ready-to-Use Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpo

[IO Summit 2022] Ready-to-Use Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors

[IO Summit 2022] Ready-to-Use Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors
Version:
21384

File Name/Number:
IO Summit

Year:
2022

Download as PDF
 

Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many cancers. Therefore, therapeutics that block inhibitory receptors or activate immuno-stimulatory checkpoint receptors have proved to be powerful agents to restore anti-tumor immune responses.